Sutro Biopharma (NASDAQ:STRO) Upgraded at Truist Financial

Truist Financial upgraded shares of Sutro Biopharma (NASDAQ:STRO) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft increased their price target on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday. Wedbush reiterated a “neutral” rating and issued a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a report on Tuesday, January 20th. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $8.00 to $27.00 in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Stock Down 1.9%

Shares of Sutro Biopharma stock opened at $24.43 on Wednesday. Sutro Biopharma has a 52 week low of $5.23 and a 52 week high of $26.54. The business has a 50 day moving average price of $19.06 and a 200-day moving average price of $12.94. The company has a market cap of $207.90 million, a PE ratio of -0.94 and a beta of 1.47.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Bridgeway Capital Management LLC raised its stake in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. Invesco Ltd. boosted its holdings in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after buying an additional 53,390 shares during the last quarter. Cerity Partners LLC grew its position in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after buying an additional 66,372 shares during the period. Qube Research & Technologies Ltd bought a new position in Sutro Biopharma during the second quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury purchased a new stake in Sutro Biopharma during the fourth quarter worth about $86,000. Institutional investors own 96.99% of the company’s stock.

More Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55, signaling strong upside from current levels; that lift to a much higher PT supports bullish investor sentiment. Deutsche Bank Raises Price Target to $55
• Positive Sentiment: Wells Fargo upgraded Sutro to “Overweight,” an endorsement that can attract institutional buying. Wells Fargo Upgrades Sutro Biopharma to Overweight
• Positive Sentiment: Truist moved the stock to “strong-buy” (reported via Zacks), another supportive vote of confidence from the sell side. Truist Upgrades to Strong-Buy (Zacks)
• Neutral Sentiment: HC Wainwright published commentary on Sutro’s FY2030 outlook — the note offers long‑range modeling context but is not a straightforward buy/sell trigger by itself. HC Wainwright Comments on Sutro FY2030 Earnings
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts (Q1–Q4 FY2026 and FY2026–FY2029), moving projected losses much deeper while keeping a Buy rating and a $28 target. Those sizable downward revisions increase short‑term downside risk and help explain selling pressure despite upgrades. HC Wainwright Lowers Multiple EPS Estimates (MarketBeat)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.